Last updated: July 5, 2026
Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc., case number 1:18-cv-01962, is a federal litigation matter filed in the District of New Jersey. The docket-level record that is required to produce a litigation “summary and analysis” (claims at issue, asserted patents, procedural posture, Markman orders, settlements/consent judgments, and any Paragraph IV/Biologics exclusivity linkage) is not provided here, so a complete and accurate case-specific analysis cannot be generated.
What is the litigation status of Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc. (1:18-cv-01962)?
Featured snippet answer: No case status details (dismissal, stay, settlement, judgment, or ongoing discovery) are available in the provided information.
What procedural events typically drive outcomes in this type of case?
A case like this usually turns on:
- Which patents are asserted (and whether they include Orange Book-listed drug patents or exclusivity-tied claims).
- Whether the court stays the case pending FDA regulatory timelines.
- Whether parties reach a settlement with an agreed launch date.
- Claim construction rulings that affect infringement/non-infringement.
What the docket needs to show to confirm status
To state status precisely, a litigation summary requires, at minimum:
- the latest docket entry date and disposition (e.g., “dismissed without prejudice,” “summary judgment granted,” “settlement and stipulation of dismissal,” or “trial occurred and judgment entered”)
- whether there is a Markman/claim construction order
- whether any motions to dismiss or summary judgment were granted or denied
Which patents were asserted in Silvergate Pharmaceuticals v. Bionpharma (1:18-cv-01962)?
Featured snippet answer: Asserted patents, their application or issuance numbers, and the asserted claims are not included in the provided information.
What patent set is commonly asserted in Silvergate-type challenges
In Hatch-Waxman (ANDA) and related exclusivity disputes, courts typically see:
- composition-of-matter claims
- formulation claims (if the dispute targets a specific dosage form or excipient system)
- method-of-use claims tied to an indication
- manufacturing method claims
How to interpret the asserted patent bundle
A defensible analysis requires:
- which patents are “listed” for the referenced NDA in the Orange Book
- whether patents include “use” patents or “drug substance” patents
- whether the case includes invalidity arguments (102/103/112) or only non-infringement
Did Silvergate bring a Paragraph IV challenge, and did exclusivity affect the case outcome?
Featured snippet answer: No Paragraph IV notice details (e.g., ANDA filer identity, notice contents, or the date of notice) are provided.
How exclusivity timelines usually govern stay and settlement
For ANDA disputes, an exclusivity or patent “expiration map” typically drives:
- 30-month stay triggers tied to the paragraph IV notice
- whether any 180-day exclusivity was claimed or forfeited
- whether FDA approval was blocked by unexpired listed patents
What determines end-to-end timeline risk
The key court and FDA-linked variables include:
- whether the court found non-infringement or invalidity
- whether an injunction issued
- whether the parties agreed a launch date that maps to specific patent expirations
What was the infringement and invalidity theory advanced by the parties?
Featured snippet answer: The infringement theory and invalidity grounds are not provided.
Typical technical/infringement issue areas
For small-molecule drug challenges, infringement analysis often focuses on:
- molecular identity and claim limitations
- bioequivalence-related formulation attributes
- process parameters if method patents are asserted
Typical invalidity issue areas
Invalidity often focuses on:
- anticipation/obviousness based on prior art references
- enablement and written description under 35 U.S.C. §112
- definiteness and claim scope
Did the court issue claim construction, summary judgment, or injunction orders?
Featured snippet answer: No orders are included in the provided information.
Why claim construction matters
If an order narrows key claim terms, it can:
- eliminate infringement under the asserted limitations
- create a final-judgment pathway via summary judgment
Why summary judgment and injunction filings matter
If the court issues:
- summary judgment on non-infringement, the generic/ANDA path often opens quickly
- summary judgment on invalidity, the patent estate collapses for the asserted claims
- an injunction, the launch timeline becomes tied to appeals and any stayed FDA approval
Were there settlement talks or a consent judgment in Silvergate v. Bionpharma?
Featured snippet answer: No settlement or consent judgment information is provided.
What settlement terms usually cover
A settlement in this context commonly addresses:
- “at-risk” launch timing
- licensing scope (often limited to certain claims or patents)
- dismissal with or without prejudice
- confidentiality and covenant not to sue terms
What is the FDA regulatory posture associated with this litigation?
Featured snippet answer: No NDA/ANDA/BLA identifiers, FDA submission pathway (ANDA 505(j), BLA 351(k), 505(b)(2)), or approval status is provided.
What FDA record fields must be known for a defensible analysis
A proper crosswalk requires:
- product name, NDA number, reference listed drug (RLD)
- ANDA number and applicant
- paragraph IV notice date and patent list referenced
- FDA approval date (or non-approval status)
- exclusivity trigger (180-day exclusivity, 3-year, 5-year, pediatric exclusivity, orphan exclusivity if applicable)
How does Bionpharma’s market entry risk change based on patent estate strength?
Featured snippet answer: Patent-asset strength cannot be assessed because asserted patents, their claims, and their litigation outcomes are not provided.
What drives generic entry risk
Entry risk is primarily governed by:
- whether patents are composition or method vs. use patents
- the likelihood of sustained validity through claim construction and summary judgment
- the existence of multiple overlapping patents with staggered expiration
- whether the court recognized “earlier” or “later” effective dates for infringement scope
Key Takeaways
- Case-specific litigation summary and analysis for Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc. (1:18-cv-01962) cannot be produced from the information provided.
- A complete and accurate analysis requires docket-linked facts (asserted patents, procedural posture, orders, and settlement/judgment status) that are not present in the prompt.
FAQs
- What patents are typically asserted in Hatch-Waxman cases involving Silvergate-style brand owners?
- How do 30-month stays work when a paragraph IV notice is filed?
- What court events most often lead to settlement in ANDA patent litigation?
- How does claim construction change an infringement/invalidity posture?
- What Orange Book information controls FDA approval timing during patent litigation?
References (APA)
- No citable sources were provided in the prompt.
